Vectus Biosystems

Vectus Biosystems OCF Margin

The Operating Cash Flow Margin of Vectus Biosystems (VBS.AX) as of Nov 5, 2026 is -173.59 %. In the previous year, Operating Cash Flow Margin was -178.52 % — a change of -2.76% (higher).

OCF Margin

-173.59 %

YoY

-2.76%

Last updated:

Operating Cash Flow Margin of Vectus Biosystems is 2025 -173.59 % . Operating Cash Flow Margin of Vectus Biosystems was 2024 -178.52 % . It decreases by -2.76% higher compared to the previous year.

The Vectus Biosystems OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-75,922.39 AUD
Jan 1, 2019
-473,005.91 AUD
Jan 1, 2020
-5,864.00 AUD
Jan 1, 2021
-1.81 M AUD
Jan 1, 2022
-341.61 AUD
Jan 1, 2023
-173.69 AUD
Jan 1, 2024
-178.52 AUD
Jan 1, 2025
-173.59 AUD
The Vectus Biosystems OCF Margin history
YEAROCF MarginYoY
-173.59 %-2.76%
-178.52 %+2.78%
-173.69 %-49.15%
-341.61 %-99.98%
-1.81 M %+30,742.92%
-5,864.00 %-98.76%
-473,005.91 %+523.01%
-75,922.39 %+862.17%
-7,890.75 %+126.89%
-3,477.74 %-93.75%
-55,604.34 %+37,397.25%
-148.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vectus Biosystems Stock analysis

What does Vectus Biosystems do? Vectus Biosystems Ltd. generates revenue through the development and commercialization of pharmaceutical products targeting fibrotic diseases and hypertension. The company focuses on VB0004, a compound designed to treat tissue hardening and high blood pressure, alongside candidates for fibrotic liver conditions like NASH and pulmonary fibrosis. Its subsidiary Accugen Pty Limited offers the Accugen platform, which provides qPCR reagents and software for accurate DNA and RNA quantification in laboratory testing. The primary buyers of these products are pharmaceutical companies and research institutions seeking advanced drug development tools and therapies for fibrotic disorders. Vectus Biosystems targets the medical research and development sector, specifically addressing unmet needs in fibrotic disease treatment. The Accugen platform serves laboratories requiring efficient molecular analysis tools, with its technology enhancing the speed and precision of qPCR testing. The company’s revenue streams are derived from both therapeutic product development and the sale of diagnostic solutions to biotech firms and academic research entities. The firm’s focus on fibrosis-related treatments, including heart, kidney, and liver diseases, positions it within niche therapeutic segments. Accugen’s reagents and software are sold to laboratories as part of the qPCR workflow, supporting drug discovery processes. Pharmaceutical companies and research organizations are the key segments purchasing Vectus Biosystems’ products for their R&D pipelines and clinical applications. Vectus Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectus Biosystems stock

Operating Cash Flow Margin of Vectus Biosystems is -173.59 % in 2025.

Operating Cash Flow Margin of Vectus Biosystems changed from -178.52 % to -173.59 %, representing a -2.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Vectus Biosystems since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Vectus Biosystems with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Vectus Biosystems

All Key Metrics — Vectus Biosystems